换一批Addition of topical pimecrolimus to once-daily mid-potent steroid confers no short-term therapeutic benefit in the treatment of severe atopic dermatitis; a randomized controlled trial.
第一作者：
J M,Spergel
第一单位：
Division of Allergy and Immunology, Children's Hospital of Philadelphia, University of Pennsylvania School of Medicine, Philadelphia, PA, USA. Spergel@email.chop.edu
作者：
医学主题词
投药, 皮肤(Administration, Cutaneous);青少年(Adolescent);成年人(Adult);老年人(Aged);雄二烯类(Androstadienes);消炎药(Anti-Inflammatory Agents);儿童(Child);儿童, 学龄前(Child, Preschool);皮炎, 特应性(Dermatitis, Atopic);皮肤科用药(Dermatologic Agents);双盲法(Double-Blind Method);药物疗法, 联合(Drug Therapy, Combination);女(雌)性(Female);人类(Humans);男(雄)性(Male);中年人(Middle Aged);疾病严重程度指数(Severity of Illness Index);他罗利姆(Tacrolimus);治疗结果(Treatment Outcome)
DOI
10.1111/j.1365-2133.2007.08001.x
PMID
17573885
发布时间
2015-11-19
- 浏览10
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
